Yaacov-Garbeli Dana 4

4 · Entera Bio Ltd. · Filed Jul 18, 2025

Form 4

Period: 2025-07-16

Chief Financial Officer

Transactions

Award
Stock Option (right to buy)
2025-07-16+130,000→ 130,000 total
Exercise: $2.28Exp: 2035-04-28→ Ordinary Shares, par value NIS 0.0000769 per share (130,000 underlying)
Award
Ordinary Shares, par value NIS 0.0000769 per share
2025-07-16+26,316→ 113,047 total(indirect: By A2Z Counseling Ltd.)

Footnotes (3)

[F1]Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2024 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025.
[F2]These shares are owned by A2Z Counseling Ltd. of which the reporting person owns a 33.33% interest and has effective control over voting and disposition of the shares. The reporting person disclaims beneficial ownership of the securities held by A2Z Counseling Ltd., except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
[F3]This grant of options was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. The options vest over a three-year period that commenced on April 28, 2025, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

Documents

1 file